Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

References

• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE, et al; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546S-92S
   Google Scholar
• Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:1070-4
   PubMed Web of Science ®Google Scholar
• Fustinoni O. The case for an elderly targeted stroke management. Front Neurol 2011;2:89--1074
   Google Scholar
• Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs 2010;10:37-48
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-2
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE Trials. J Med Econ 2012;15:776-85.
   PubMedGoogle Scholar
• Bureau of Labor Statistics US Department of Labor. Consumer Price Index December 2010. USDL-11-0018. 2010. Washington DC. http://www.bls.gov/news.release/archives/cpi_01142011.pdf. Accessed January 11, 2012
   Google Scholar
• Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-8
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Throm Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Scheiman J, Fendrick AM, et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011;171:218-25
   PubMedGoogle Scholar
• Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
   PubMed Web of Science ®Google Scholar
• Center for Medicare and Medicaid Services. Medicare Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing: Medicare Fee Schedule for Office Visit CPT Codes - 2011, CPT Code 99213, 99214, 99203. 2011. Baltimore, MD. http://www.medicarepaymentandreimbursement.com/p/medicare-fee-schedule-for-office-visit.html. Accessed February 29, 2012
   Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
   PubMed Web of Science ®Google Scholar
• Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96
   PubMed Web of Science ®Google Scholar
• Analy$ource Online. First Databank Inc. San Francisco, CA. 2013. DMD America, Syracuse, NY
   Google Scholar
• Harrington AR, Armstrong EP, Nolan PE, Jr et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
   PubMed Web of Science ®Google Scholar
• The Henry J Kaiser Family Foundation. U.S. health care costs: issue modules, background brief. 2012. Menlo Park, CA. http://www.kaiseredu.org/Issue-Modules/US-Health-Care-Costs/Background-Brief.aspx. Accessed March 2, 2012
   Google Scholar